OMA Guidelines Bundle

Obesity Pharmacotherapy Supplements 2026

Obesity Medicine Association OMA GUIDELINES App Bundle brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1544296

Contents of this Issue

Navigation

Page 16 of 19

17 Key Interactions/Notes Avg. ΔWt vs. Placebo Carbonic anhydrase inhibitors (CAIs) (eg, topiramate, zonisamide) lactic acidosis risk ~3% Delays gastric emptying → may delay absorption of oral meds ~5% Effect of OCs; potentiates central nervous system (CNS) depressants and hypokalemia with non–K-sparing diuretics ~2–5% CYP2D6 inhibitor ~4–5% CYP2D6 substrate ~5% CYP3A4 metabolism ~3.1–5%

Articles in this issue

Archives of this issue

view archives of OMA Guidelines Bundle - Obesity Pharmacotherapy Supplements 2026